The estimated Net Worth of Anna Berkenblit is at least $5.4 Million dollars as of 24 February 2020. Ms. Berkenblit owns over 25,803 units of Immunogen stock worth over $3,064,300 and over the last 8 years she sold IMGN stock worth over $522,702. In addition, she makes $1,808,700 as Senior Vice President and Chief Medical Officer at Immunogen.
Anna has made over 6 trades of the Immunogen stock since 2017, according to the Form 4 filled with the SEC. Most recently she sold 25,803 units of IMGN stock worth $128,757 on 24 February 2020.
The largest trade she's ever made was selling 25,803 units of Immunogen stock on 24 February 2020 worth over $128,757. On average, Anna trades about 3,169 units every 39 days since 2017. As of 24 February 2020 she still owns at least 98,089 units of Immunogen stock.
You can see the complete history of Ms. Berkenblit stock trades at the bottom of the page.
Anna Berkenblit serves as Senior Vice President and Chief Medical Officer of the Company.D. serves as Vice President and Chief Medical Officer of ImmunoGen, Inc. She joined ImmunoGen in 2015, and has served as our Vice President and Chief Medical Officer since that date. Prior to joining ImmunoGen, she served as Senior Vice President and Head of Clinical Research at H3 Biomedicine Inc., a pharmaceutical company, from 2013 to 2015. Prior to that she served as Vice President and Head of Clinical Research at AVEO Pharmaceuticals, Inc., a biopharmaceutical company, from 2011 to 2013. Prior to that she spent five years at the oncology business unit of Pfizer Inc. (and Wyeth, prior to its acquisition by Pfizer) in roles of increasing responsibility related to medical research and clinical development. Dr. Berkenblit holds a Doctor of Medicine degree from Harvard Medical School and a master’s degree from the Harvard/MIT Health & Sciences clinical investigator training program.
As the Senior Vice President and Chief Medical Officer of Immunogen, the total compensation of Anna Berkenblit at Immunogen is $1,808,700. There are 1 executives at Immunogen getting paid more, with Mark Enyedy having the highest compensation of $3,917,560.
Anna Berkenblit is 49, she's been the Senior Vice President and Chief Medical Officer of Immunogen since 2019. There are 14 older and 2 younger executives at Immunogen. The oldest executive at Immunogen, Inc. is Richard Wallace, 68, who is the Independent Director.
Anna's mailing address filed with the SEC is C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM, MA, 02451.
Over the last 21 years, insiders at Immunogen have traded over $72,947,831 worth of Immunogen stock and bought 303,125 units worth $974,603 . The most active insiders traders include Biochem Incshire Pharmaceut..., Capital, L.P.Morton Holding..., and Mark J Enyedy. On average, Immunogen executives and independent directors trade stock every 34 days with the average trade being worth of $2,554,057. The most recent stock trade was executed by Stacy Ann Coen on 2 February 2024, trading 14,350 units of IMGN stock currently worth $448,294.
immunogen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics with its proprietary antibody-drug conjugate (adc) technology. the company's lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α-positive ovarian cancers and other solid tumors. leading healthcare companies have licensed rights to use immunogen's technology to develop novel anticancer therapies, and roche's marketed product, kadcyla, utilizes immunogen's adc technology. more information about the company can be found at www.immunogen.com.
Immunogen executives and other stock owners filed with the SEC include: